Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models

Pseudopaline–aztreonam conjugates exhibited enhanced antimicrobial activity against Pseudomonas aeruginosa compared to aztreonam alone

The gut shares its bacterial population with the lungs and influences their inflammatory status.

The antibiotic cefiderocol at low concentrations reduces the number of persistent P. aeruginosa cells both in vitro and in vivo.

Development of inhalable nanoparticles based on biopolymers to deliver antimicrobial molecules and antibiotics and enhance their antibacterial activity.

VOMG blocks the growth of M. abscessus by inhibiting the FtsZ protein and enhances the activity of the antibiotic amikacin in vitro and in vivo

Several drugs already approved for human use inhibit the growth of P. aeruginosa, its virulence, or its ability to form biofilms in vitro

A phage-derived endolysin is effective in vitro in eliminating Mycobacterium abscessus

Panobinostat reduces the amount of lipids in alveolar macrophages infected with Mab, inhibiting bacterial replication.

GE-vesicles efficiently deliver the CRISPR system into cell models, enabling the correction of certain CFTR mutations.

GM1 and cholesterol enhance CFTR modulator activity and immune responses in vitro

Characterization of CFTR modulators mechanism of action via Photo-Affinity Labeling (PAL) approach

The PI3Kγ peptide has a stabilizing effect on CFTR and enhances the effect of Kaftrio

Esc peptides stabilize the opening of the CFTR channel and exhibit antibacterial activity against P. aeruginosa and S. aureus both in vitro and in vivo models

The chemical structure of inhibitors of the salicylate synthase enzyme from Mycobacterium abscessus has been identified to reduce the bacterium's virulence

Search for drug combinations killing Mycobacterium abscessus in cystic fibrosis

Identification of the main Mycobacterium abscessus variants in Italy and markers of lung disease stages

Effect of inflammatory stimuli on airway epithelium ion transport in cystic fibrosis

GY971a has demonstrated anti-inflammatory activity without showing toxicity either in vitro on cells or in vivo models

Resolvin D3 and Resolvin E1 are able to reduce platelet hyperactivation in vitro, modulating the inflammatory response in the airways

The DEV phage has anti-inflammatory effects and, in zebrafish, acts on macrophages by modulating their activity

The combined therapy of liposomes and amikacin is able to combat Mycobacterium abscessus infection and reduce inflammation in both in vitro and in vivo models

The DNase1 and DNase1L2 enzymes, modified through PEGylation, more effectively reduce mucus viscosity compared to the unmodified enzyme

IL-17F cytokine production is associated with increased IgE and pulmonary inflammation in allergic bronchopulmonary aspergillosis in children with CF

Multiomics exploration of the CF primary bronchial epithelium lipidome and its role on CFTR rescue

Harnessing CRISPR-Cas technology to revert F508del and 2789+5G>A CFTR defects

Toward the development of tailored therapies for insensitive CF gating mutations

Oxidative stress and autophagy in Cystic Fibrosis: Novel biochemical characterizations and drug discovery approaches

In vitro evaluation of novel sequence-specific RNA editing tools to rescue nonsense mutant CFTR transcript

Enhancing the prediction of clinical responses to CFTR modulators by in vitro assays using patient-derived tissues under conditions mimicking native status of CF airways

Monocyte integrin activation as a cystic fibrosis drug evaluation test: validation phase

Theratyping of cystic fibrosis

Lead optimization of MKT-077 analogues as HSP70 allosteric inhibitors combined with F508del CFTR correctors: a multi-drug approach to contrast cystic fibrosis

Theratyping orphan mutations in Italian cystic fibrosis patients: meeting unmet needs

Alternative targets for the treatment of cystic fibrosis basic defect

Pharmacological inhibition of colistin resistance in Gram-negative cystic fibrosis pathogens

Probiotics: an emerging strategy to fight bacterial pulmonary infections in CF

Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against Pseudomonas aeruginosa

Tackling phage resistance to increase the robustness of phage therapy for curing Pseudomonas aeruginosa infections in patients with cystic fibrosis (PhaCyf)

Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease

New drug combinations against non-tuberculous mycobacteria infections in cystic fibrosis

New weapons against Mycobacterium abscessus and other nontuberculous Mycobacteria

Exploring the dual targeting of host and microbial sphingosine-1-phosphate lyase as antimicrobial strategy in cystic fibrosis

Nanotechnology-based Resolvin D1 as Proresolving Therapy in Cystic Fibrosis: Preclinical Studies for the Delivery of Innovative Formulations to the Clinic

Mental Health in cystic fibrosis patients: the prognostic role of temperament, personality and attachment styles

Peptide-nucleic acids as potential CFTR amplifier molecules for cystic fibrosis treatment

Lipid-based therapeutic strategies to optimize the effectiveness of innovative drugs to rescue F508del-CFTR

Small nitrogen heterocycles as correctors of the mutant CFTR protein in cystic fibrosis